Global Clinical Platform Biosion's lead asset BSI-045B is in four clinical trials with the most advanced in Phase 3, and the company operates in the US, Australia, and China, enabling multi-region engagement and cross-border licensing or co-development opportunities.

Strategic Partnerships Recent licensing activity demonstrates strong partner interest: Aclaris acquired global rights (excluding China) to two inflammatory candidates, and CT Tianqing secured an exclusive Greater China license to BSI-038, signaling a robust pathway for regional commercialization and collaboration.

Pipeline Expansion Biosion plans to bring additional oncology assets into the clinic over the next year, supported by internally developed platforms such as H3 antibody discovery, SynTracer HT-endocytosis, and Flexibody bispecifics, offering multiple BD entry points.

Financial Traction The company reports revenue in the range of 50 to 100 million and recently secured financing around 40 million, indicating meaningful funds to accelerate clinical development and strategic partnerships.

Leadership Growth Kedan Lin was appointed Chief Development Officer and President of Biosion US, underscoring a sharpened US market focus and strengthened leadership for business development and clinical execution.